Viallard C, Larrivee B. Blood — Anti-angiogenesis in regenerative medicine, Organic brown rice myeloid cells meficine their Anti-angipgenesis into tumour sites may break the jinx. Melincovici, C. The application of biomarkers is a powerful adjuvant means which are essential for disease identification, early diagnosis and prevention, and drug treatment monitoring.

Anti-angiogenesis in regenerative medicine -

Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Gianni-Barrera R , Bartolomeo M , Vollmar B , Djonov V , Banfi A. Split for the cure: VEGF, PDGF-BB and intussusception in therapeutic angiogenesis.

Egginton S , Zhou AL , Brown MD , Hudlická O. Unorthodox angiogenesis in skeletal muscle. Cardiovasc Res. Gianni-Barrera R , Trani M , Fontanellaz C , et al. VEGF over-expression in skeletal muscle induces angiogenesis by intussusception rather than sprouting.

Al Haj Zen A , Oikawa A , Bazan-Peregrino M , et al. Inhibition of delta-likemediated signaling impairs reparative angiogenesis after ischemia. Makanya AN , Hlushchuk R , Djonov VG.

Intussusceptive angiogenesis and its role in vascular morphogenesis, patterning, and remodeling. Egginton S. Invited review: activity-induced angiogenesis. Pflugers Arch. De Spiegelaere W , Casteleyn C , Van den Broeck W , et al.

Intussusceptive angiogenesis: a biologically relevant form of angiogenesis. J Vasc Res. Dimova I , Hlushchuk R , Makanya A , et al. Inhibition of notch signaling induces extensive intussusceptive neo-angiogenesis by recruitment of mononuclear cells.

Dill MT , Rothweiler S , Djonov V , et al. Disruption of Notch1 induces vascular remodeling, intussusceptive angiogenesis, and angiosarcomas in livers of mice. e - Gianni-Barrera R , Butschkau A , Uccelli A , et al. PDGF-BB regulates splitting angiogenesis in skeletal muscle by limiting VEGF-induced endothelial proliferation.

Groppa E , Brkic S , Uccelli A , et al. EMBO Rep. Bjarnegard M , Enge M , Norlin J , et al. Endothelium-specific ablation of PDGFB leads to pericyte loss and glomerular, cardiac and placental abnormalities. Lindahl P , Johansson BR , Leveen P , et al. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice.

Lindblom P , Gerhardt H , Liebner S , et al. Endothelial PDGF-B retention is required for proper investment of pericytes in the microvessel wall. Armulik A , Genove G , Betsholtz C. Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev Cell.

Sato Y , Rifkin DB. Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-beta 1-like molecule by plasmin during co-culture. Goumans MJ , Valdimarsdottir G , Itoh S , Rosendahl A , Sideras P , ten Dijke P.

Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J. van Meeteren LA , ten Dijke P. Regulation of endothelial cell plasticity by TGF-beta.

Cell Tissue Res. Fagiani E , Christofori G. Angiopoietins in angiogenesis. Cancer Lett. Pasquale EB. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Erber R , Eichelsbacher U , Powajbo V , et al. EphB4 controls blood vascular morphogenesis during postnatal angiogenesis.

Foo SS , Turner CJ , Adams S , et al. Ephrin-B2 controls cell motility and adhesion during blood-vessel-wall assembly. Sawamiphak S , Seidel S , Essmann CL , et al. Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis.

Wang Y , Nakayama M , Pitulescu ME , et al. Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. Murdoch C , Muthana M , Coffelt SB , Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis.

Grunewald M , Avraham I , Dor Y , et al. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Dimova I , Karthik S , Makanya A , et al. De Palma M , Naldini L. Tie2-expressing monocytes TEMs : novel targets and vehicles of anticancer therapy?

Biochim Biophys Acta. Zacchigna S , Pattarini L , Zentilin L , et al. Bone marrow cells recruited through the neuropilin-1 receptor promote arterial formation at the sites of adult neoangiogenesis in mice.

J Clin Invest. Groppa E , Brkic S , Bovo E , et al. EMBO Mol Med. Lee RJ , Springer ML , Blanco-Bose WE , Shaw R , Ursell PC , Blau HM.

VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Schwarz ER , Speakman MT , Patterson M , et al. Evaluation of the effects of intramyocardial injection of DNA expressing vascular endothelial growth factor VEGF in a myocardial infarction model in the rat—angiogenesis and angioma formation.

J Am Coll Cardiol. Springer ML , Chen AS , Kraft PE , et al. VEGF gene delivery to muscle: potential role for vasculogenesis in adults. Mol Cell. Sundberg C , Nagy JA , Brown LF , et al.

Am J Pathol. Ozawa CR , Banfi A , Glazer NL , et al. Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. von Degenfeld G , Banfi A , Springer ML , et al. Microenvironmental VEGF distribution is critical for stable and functional vessel growth in ischemia.

FASEB J. Boden J , Lassance-Soares RM , Wang H , et al. Vascular regeneration in ischemic Hindlimb by adeno-associated virus expressing conditionally silenced vascular endothelial growth factor. J Am Heart Assoc. Ylä-Herttuala S , Baker AH. Cardiovascular gene therapy: past, present, and future.

Mol Ther. Misteli H , Wolff T , Fuglistaler P , et al. High-throughput flow cytometry purification of transduced progenitors expressing defined levels of vascular endothelial growth factor induces controlled angiogenesis in vivo.

Stem Cells. Helmrich U , Marsano A , Melly L , et al. Tissue Eng Part C Methods. Wolff T , Mujagic E , Gianni-Barrera R , et al. FACS-purified myoblasts producing controlled VEGF levels induce safe and stable angiogenesis in chronic hind limb ischemia.

Melly LF , Marsano A , Frobert A , et al. Controlled angiogenesis in the heart by cell-based expression of specific vascular endothelial growth factor levels. Hum Gene Ther Methods. Melly L , Cerino G , Frobert A , et al. Myocardial infarction stabilization by cell-based expression of controlled vascular endothelial growth factor levels.

Marsano A , Maidhof R , Luo J , et al. The effect of controlled expression of VEGF by transduced myoblasts in a cardiac patch on vascularization in a mouse model of myocardial infarction. Boccardo S , Gaudiello E , Melly L , et al.

Engineered mesenchymal cell-based patches as controlled VEGF delivery systems to induce extrinsic angiogenesis. Acta Biomater. Helmrich U , Di Maggio N , Guven S , et al.

Osteogenic graft vascularization and bone resorption by VEGF-expressing human mesenchymal progenitors. Browne S , Pandit A. Engineered systems for therapeutic angiogenesis. Curr Opin Pharmacol. Martino MM , Brkic S , Bovo E , et al. Extracellular matrix and growth factor engineering for controlled angiogenesis in regenerative medicine.

Front Bioeng Biotechnol. Addi C , Murschel F , De Crescenzo G. Design and use of chimeric proteins containing a collagen-binding domain for wound healing and bone regeneration. Tissue Eng Part B Rev. Bao P , Kodra A , Tomic-Canic M , Golinko MS , Ehrlich HP , Brem H.

The role of vascular endothelial growth factor in wound healing. J Surg Res. Zisch AH , Schenk U , Schense JC , Sakiyama-Elbert SE , Hubbell JA. Covalently conjugated VEGF—fibrin matrices for endothelialization. J Control Release.

Sacchi V , Mittermayr R , Hartinger J , et al. Long-lasting fibrin matrices ensure stable and functional angiogenesis by highly tunable, sustained delivery of recombinant VEGF Proc Natl Acad Sci USA.

Martino MM , Tortelli F , Mochizuki M , et al. Engineering the growth factor microenvironment with fibronectin domains to promote wound and bone tissue healing. Sci Transl Med. Martino MM , Briquez PS , Guc E , et al. Growth factors engineered for super-affinity to the extracellular matrix enhance tissue healing.

Reevaluation of the role of VEGF-B suggests a restricted role in the revascularization of the ischemic myocardium. Arterioscler Thromb Vasc Biol. Kivela R , Bry M , Robciuc MR , et al. VEGF-B-induced vascular growth leads to metabolic reprogramming and ischemia resistance in the heart.

Lahteenvuo JE , Lahteenvuo MT , Kivela A , et al. Vascular endothelial growth factor-B induces myocardium-specific angiogenesis and arteriogenesis via vascular endothelial growth factor receptor and neuropilin receptordependent mechanisms. Rissanen TT , Markkanen JE , Gruchala M , et al.

VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. Health USNIo.

Adenovirus Vascular Endothelial Growth Factor D AdvVEGF-D Therapy for Treatment of Refractory Angina Pectoris ReGenHeart. Accessed September 24, Hartikainen J , Hassinen I , Hedman A , et al.

Eur Heart J. Banfi A , von Degenfeld G , Gianni-Barrera R , et al. Therapeutic angiogenesis due to balanced single-vector delivery of VEGF and PDGF-BB. Gianni-Barrera R , Burger M , Wolff T , et al. Long-term safety and stability of angiogenesis induced by balanced single-vector co-expression of PDGF-BB and VEGF in skeletal muscle.

Sci Rep. Korpisalo P , Karvinen H , Rissanen TT , et al. Vascular endothelial growth factor-a and platelet-derived growth factor-B combination gene therapy prolongs angiogenic effects via recruitment of interstitial mononuclear cells and paracrine effects rather than improved pericyte coverage of angiogenic vessels.

Kupatt C , Hinkel R , Pfosser A , et al. Cotransfection of vascular endothelial growth factor-a and platelet-derived growth factor-B via recombinant adeno-associated virus resolves chronic ischemic malperfusion. Role of vessel maturation.

IntechOpen Regenerative Medicine and Tissue Engineering Edited by Jose A. From the Edited Volume Regenerative Medicine and Tissue Engineering Edited by Jose A. Andrades Book Details Order Print. Chapter metrics overview 2, Chapter Downloads View Full Metrics.

Impact of this chapter. Introduction Regenerative concepts are one of the basic ideas of modern biomedical research. Angiogenesis versus vasculogenesis Lack of oxygen and nutrients threatens the tissue integrity and viability fundamentally. VEGF pathway The healthy vasculature is one prerequisite of every regenerative process.

Role of endothelial cells Endothelial cells are the cellular key element of angiogenesis and play a significant role in all crucial steps: Endothelial cells are able to produce and release growth factors.

Endothelial cells are actively involved in the dissolution of the surrounding matrix. Simultaneously the migration adhesion and proliferation of endothelial cells continues. Physiology Hypoxia is one of the most potent inductors of angiogenesis.

Oxygen sensing Cellular mechanisms of oxygen regulation concern the aerobe glycolysis, the arrest of the cell cycle end the initiation of apoptosis. HIF-1 alpha Hypoxia inducible factor 1 alpha HIF-1 alpha is the key regulator of cellular and systemic oxygen haemostasis.

Target genes A plethora of target genes are governed by hypoxia via HIF The following tables summarize the most relevant genes according to their function in the context of angio- and vasculogenesis Extracellular matrix proteins and enzymes Angiogenic growth factors and cytokines Cell surface receptors MMP2 ANGPT1 and 2 CXCR4 FN1 EPO VEGFR 2 COL5A1 IGF2 TFRC PLAUR VEGF TGFA and B.

Table 1. Extracelullar targets. Cytoskeletal proteins Proapoptotic proteins Transcription factors Glucose tranporters and glycolytic enzymes KRT14 RTP DEC1 GLUT1 and 3 KRT18 NIP3 DEC2 ENO1 KRT19 NIX ETS1 HK1 and 2 VIM CITED2 LDHA TPI PGK1.

Table 2. Intracellular targets. Clinical relevance The functionality of HIF-1 alpha, its capacity to transmit the need for oxygen and therefore for more vasculature has been the basic idea of innovative therapeutic concepts. Therapeutic angiogenesis In different clinical applications the angiogenic effect of different growth and transcription factors could be observed.

Table 3. Nanotechnology in regenerative medicine Modern biomaterials have to meet many requirements: not only do they have to provide mechanic support and stability; they have also to enhance regenerative processes, to be anti-infective and non-inflammatory.

Critical aspects Many promising investigations featuring growth factor therapy are performed in cell culture or healthy young animals. Embryonic stem cells Human embryonic stem cells are capable of self-renewal and differentiation in cells from all germ layers.

Mesenchymal stem cells In contrast to embryonic stem cells, mesenchymal stem cells are characterized by pluripotency. References 1.

Autiero M Waltenberger J Communi D Kranz A Moons L Lambrechts D Kroll J Plaisance S De Mol M Bono F Kliche S Fellbrich G Ballmer-hofer K Maglione D Mayr-beyrle U Dewerchin M Dombrowski S Stanimirovic D Van Hummelen P Dehio C Hicklin D.

J Persico G Herbert J. M Communi D Shibuya M Collen D Conway E. M Carmeliet P Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1, Nat Med.

Barralet J Gbureck U Habibovic P Vorndran E Gerard C Doillon C. J Angiogenesis in calcium phosphate scaffolds by inorganic copper ion release, Tissue Eng Part A. Behonick D. J Xing Z Lieu S Buckley J. M Lotz J. C Marcucio R. S Werb Z Miclau T Colnot C Role of matrix metalloproteinase 13 in both endochondral and intramembranous ossification during skeletal regeneration, PLoS One.

Breen E. C VEGF in biological control, J Cell Biochem. Bruegge K Jelkmann W Metzen E Hydroxylation of hypoxia-inducible transcription factors and chemical compounds targeting the HIF-alpha hydroxylases, Curr.

Carpenter J Khang D Webster T. J Nanometer polymer surface features: the influence on surface energy, protein adsorption and endothelial cell adhesion , Nanotechnology. Cima L. G Vacanti J. P Vacanti C Ingber D Mooney D Langer R Tissue engineering by cell transplantation using degradable polymer substrates, J Biomech Eng 51 8.

Colnot C Thompson Z Miclau T Werb Z Helms J. A Altered fracture repair in the absence of MMP9, Development. Descamps B Emanueli C Vascular differentiation from embryonic stem cells: novel technologies and therapeutic promises, Vascul Pharmacol. Epub Apr 2.

Dhillon R. S Schwarz E. M Teriparatide Therapy as an Adjuvant for Tissue Engineering and Integration of Biomaterials, J Mater Res. Dyer L. A Portbury A. L Patterson C Gyrate: CCM3 dances with a different angiogenic partner, Sci Signal.

Frerich B Kurtz-hoffmann J Lindemann N Müller S Untersuchungen zum Tissue engineering vaskularisierter knöcherner und weichgewebiger Transplantate, 4 Suppl 2 Glowacki J Shustermann M Troulis M Holmes R Perrott D Kaban L.

B Distraction Osteogenesis of the Porcine Mandible: Histomorphometric Evaluation of Bone, Plast Reconstr Surg Hankenson K. D Dishowitz M Gray C Schenker M Angiogenesis in bone regeneration, Injury. Hollinger J. O Onikepe A. O MacKrell J, Einhorn T, Bradica G, Lynch S, Hart CE.

Jacobsen K. A Al-aql Z. S Wan C Fitch J. L Stapleton S. N Mason Z. D Cole R. M Gilbert S. R Clemens T. L Morgan E. F Einhorn T. A Gerstenfeld L. C Bone formation during distraction osteogenesis is dependent on both VEGFR1 and VEGFR2 signaling, J Bone Miner Res.

Kaigler D Wang Z Horger K Mooney D. J Krebsbach P. H VEGF scaffolds enhance angiogenesis and bone regeneration in irradiated osseous defects, J Bone Miner Res.

Kalluri R Basement membranes: structure, assembly and role in tumour angiogenesis, Nat Rev Cancer. Kane N. M Xiao Q Baker A. H Luo Z Xu Q Emanueli C Pluripotent stem cell differentiation into vascular cells: a novel technology with promises for vascular re generation. Pharmacol Ther.

Khang D Carpenter J Chun Y. W Pareta R Webster T. J Nanotechnology for regenerative medicine, Biomed Microdevices. Khang D Lu J Yao C Haberstroh K. M Webster T. J The role of nanometer and sub-micron surface features on vascular and bone cell adhesion on titanium, Biomaterials.

Lokmic Z Stillaert F Morrison W. A Thompson E. W Mitchell G. M An arteriovenous loop in a protected space generates a permanent, highly vascular, tissue-engineered construct, FASEB J.

Losordo D. W Dimmeler S Therapeutic angiogenesis and vasculogenesis for ischemic disease. Part I: angiogenic cytokines, Circulation. Lu J Rao M. P MacDonald NC, Khang D, Webster TJ. Maynard S. E Min J. Y Merchan J Lim K. H Li J Mondal S Libermann T. A Morgan J.

P Sellke F. W Stillman I. E Epstein F. H Sukhatme V. P Karumanchi S. A Excess placental soluble fms-like tyrosine kinase 1 sFlt1 may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia , J Clin Invest.

Metzen E Ratcliffe P. J HIF hydroxylation and cellular oxygen sensing, Biol Chem. Marxsen J. H Stengel P Doege K Heikkinen P Jokilehto T Wagner T Jelkmann W Jaakkola P Metzen E Hypoxia-inducible factor-1 HIF-1 promotes its degradation by induction of HIF-alpha-prolyl- 4 hydroxylases, Biochem J.

Narayan D Venkatraman S. S Effect of pore size and interpore distance on endothelial cell growth on polymers, J Biomed Mater Res A. Nomi M Atala A Coppi P. D Soker S Principals of neovascularization for tissue engineering, Mol Aspects Med. Nyberg P Salo T Kalluri R Tumor microenvironment and angiogenesis, Front Biosci.

Pandya N. M Dhalla N. S Santani D. D Angiogenesis--a new target for future therapy, Vascul Pharmacol. Park C Afrikanova I Chung Y. S Zhang W. J Arentson E Fong Gh G, Rosendahl A, Choi K.

Pearson S Sroczynska P Lacaud G Kouskoff V The stepwise specification of embryonic stem cells to hematopoietic fate is driven by sequential exposure to Bmp4, activin A, bFGF and VEGF, Development.

Pelissier P Villars F Mathouli-pelissier S Bareille R Lafage-proust M. H Vilamitjana-amedee J Influence of vascularisation and osteogenic cells on ectopic bone formation within a madreporic ceramic in rats, Plast Reconstr Surg 6 ; 41 Portal-núñez S Lozano D Esbrit P Role of angiogenesis on bone formation, Histol Histopathol.

Putnam A. J Mooney D. J Tissue engineering using synthetic extracellular matrizes, Nat Med 2 26 Richardson T. P Peters M. C Ennett A. B Mooney D. J Polymeric system for dual growth factor delivery, Nat Biotechnol. Saadeh P. B Khoslah R. K Mehrara B. J Steinbrech D. S Mccormick S. A Devore D.

P Longaker M. T Repair of a Critical Size Defect in the Rat Mandible Using allogenic Type I Collagen, J Craniof Surg 12 Santos M. I Reis R. L Vascularization in bone tissue engineering: physiology, current strategies, major hurdles and future challenges, Macromol Biosci.

Sato M Webster T. J Nanobiotechnology: implications for the future of nanotechnology in orthopedic applications, Expert Rev Med Devices.

Schänzer A Wachs F. P Wilhelm D Acker T Cooper-kuhn C Beck H Winkler J Aigner L Plate K. H Kuhn H. G Direct stimulation of adult neural stem cells in vitro and neurogenesis in vivo by vascular endothelial growth factor, Brain Pathol.

Semenza G. L HIF-1 and mechanisms of hypoxia sensing. Curr Opin Cell Biol. Storkebaum E Lambrechts D Dewerchin M Moreno-murciano M. HIF-1 at the crossroads of hypoxia, inflammation, and cancer. Int J Cancer. Jeong W, Rapisarda A, Ryun S, Robert P, Chen A, Melillo G, et al.

Pilot trial of EZN, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha HIF-1α , in patients with refractory solid tumors. Cancer Chemother Pharmacol.

Eatock MM, Tebbutt NC, Bampton CL, Strickland AH, Van Cutsem E, Nanayakkara N, et al. Phase II randomized, double-blind, placebo-controlled study of AMG trebananib in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer. Ann Oncol.

Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. Loges S, Schmidt T, Carmeliet P. Mechanisms of resistance to anti-Angiogenic therapy and development of third-generation anti-Angiogenic drug candidates.

Genes Cancer. Viallard C, Larrivee B. Tumor angiogenesis and vascular normalization: alternative therapeutic targets. Shojaei F, Ferrara N. Drug Resist Updat. Orimo A, Gupta PB, Sgroi DC, Arenzana-seisdedos F, Delaunay T, Naeem R, et al.

Guo W, Giancotti FG. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol. Yu JL, Rak JW, Coomber BL, Hicklin DJ, Kerbel RS. Effect of p53 status on tumor response to antiangiogenic therapy. Science Article CAS Google Scholar.

Zarrin B, Zarifi F, Vaseghi G, Javanmard SH. Acquired tumor resistance to antiangiogenic therapy: mechanisms at a glance. J Res Med Sci. Goel S, Wong AH, Jain RK. Vascular normalization as a therapeutic strategy. Cold Spring Harb Perspect Med. Article Google Scholar. Ramjiawan RR, Griffioen AW, Duda DG.

Anti-angiogenesis for cancer revisited: is there a role for combinations with immunotherapy? Article PubMed PubMed Central Google Scholar. Yasuda S, Sho M, Yamato I, Yoshiji H, Wakatsuki K, Nishiwada S, et al. Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 VEGFR2 induces synergistic anti-tumour effectin vivo.

Clin Exp Immunol. Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Hillan K, Koeppen K, Tobin P, Pham T.

The role of VEGF expression in response to bevacizumab plus capecitabine in metastatic breast cancer MBC. Proc Am Soc Clin Oncol. Escudier B, Eisen T, Stadler WM, Szczylik C, Demkow T, Hutson TE, et al.

Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase iii treatment approaches in renal cancer global evaluation trial. Reinmuth N, Thomas M, Meister M, Schnabel PA, Kreuter M. Current data on predictive markers for anti-angiogenic therapy in thoracic tumours.

Eur Respir J. Kim C, Yang H, Fukushima Y, Saw PE, Lee J, Park JS, et al. Vascular RhoJ is an effective and selective target for tumor angiogenesis and vascular disruption. Martinetti A, Miceli R, Sottotetti E, Di Bartolomeo M, De Braud F, Gevorgyan A, et al.

Circulating biomarkers in advanced colorectal cancer patients randomly assigned to three bevacizumab-based regimens. Cancers Basel. Tran HT, Liu Y, Zurita AJ, Lin Y, Baker-neblett KL, Martin A, et al. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.

Sammarco G, Gallo G, Vescio G, Picciariello A, Paola DG, Trompetto M, et al. Mast cells, micrornas and others: the role of translational research on colorectal cancer in the forthcoming era of precision medicine. J Clin Med. Ammendola M, Sacco R, Sammarco G, Luposella M, Patruno R, Gadaleta COD, et al.

Mast cell-targeted strategies in cancer therapy. Transfus Med Hemother. Angelucci A, Di Padova M. Int J Mol Sci. Meert A-P, Paesmans M, Martin B, Delmotte P, Berghmans T, Verdebout J-M, et al.

The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with. Br J Cancer. Jubb AM, Hurwitz HI, Bai W, Holmgren EB, Tobin P, Guerrero AS, et al. Impact of vascular endothelial growth factor-a expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer.

Shiroishi MS, Boxerman JL, Pope WB. Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma. Vasudev NS, Reynolds AR. Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.

Rojas JD, Lin F, Chiang Y, Chytil A, Chong DC, Bautch VL, et al. Ultrasound molecular imaging of VEGFR-2 in clear-cell renal cell carcinoma tracks disease response to antiangiogenic and notch-inhibition therapy.

Touyz RM, Herrmann J. Cardiotoxicity with vascular endothelial growth factor inhibitor therapy. NPJ Precis Oncol. Touyz RM, Lang NN. Hypertension and antiangiogenesis the Janus face of VEGF inhibitors. JACC Cardio Oncol. Dobbin SJH, Cameron AC, Petrie MC, Jones RJ, Touyz RM, Lang NN.

Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors. de la Torre P, Pérez-Lorenzo MJ, Alcázar-garrido Á, Flores AI. Cell-based nanoparticles delivery systems for targeted cancer therapy: lessons from anti-angiogenesis treatments.

Mukherjee S, Patra CR. Therapeutic application of anti-angiogenic nanomaterials in cancers. Liu H, Zhang Y, Zheng S, Weng Z, Ma J, Li Y, et al.

Biochemical and biophysical research communications detention of copper by sulfur nanoparticles inhibits the proliferation of A malignant melanoma and MCF-7 breast cancer cells. Biochem Biophys Res Commun.

Potdar PD, Shetti AU. Chitosan nanoparticles: an emerging weapon against the cancer. MOJ Cell Sci Rep. Trickler WJ, Nagvekar AA, Dash AK.

A novel nanoparticle formulation for sustained paclitaxel delivery. AAPS PharmSciTech. Download references. Nuffield Department of Population Health, University of Oxford, Oxford, UK. Institute of Cardiovascular Science, University College London, London, UK. Ayodipupo S. Department of Basic Science, Prince Sultan Bin Abdulaziz College for Emergency Medical Services, King Saud University, Riyadh, Saudi Arabia.

You can also search for this author in PubMed Google Scholar. ASO conceptualized the topic, designed the study methodology, conducted the literature search, and wrote the initial draft.

FA, MA, AA and MB conceptualized the topic, conducted the literature search and contributed to the initial draft. The authors read and approved the final draft of the manuscript and take responsibility for this paper. Correspondence to Ayodipupo S. Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material.

If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. Reprints and permissions. Oguntade, A. et al. Anti-angiogenesis in cancer therapeutics: the magic bullet.

J Egypt Natl Canc Inst 33 , 15 Download citation. Received : 18 November Accepted : 08 June Published : 02 July Anyone you share the following link with will be able to read this content:. Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative. Skip to main content. Search all SpringerOpen articles Search.

Download PDF. Narrative Review Open access Published: 02 July Anti-angiogenesis in cancer therapeutics: the magic bullet Ayodipupo S. Oguntade ORCID: orcid. Abstract Background Angiogenesis is the formation of new vascular networks from preexisting ones through the migration and proliferation of differentiated endothelial cells.

Main body of the abstract MEDLINE and EMBASE databases were searched for publications on antiangiogenic therapy in cancer therapeutics from to Short conclusion Clinical surveillance is important for the early detection of tumour resistance and treatment failure using reliable biomarkers.

Background Cancers still account for significant morbidity and mortality globally despite remarkable advances in the management of cancers [ 1 ]. Main text We searched MEDLINE and EMBASE for publications on anti-angiogenesis in cancer from to as part of a larger project on anti-angiogenesis and cancer therapeutics.

Anti-angiogenics in cancers Several preclinical and clinical studies in cancer research have targeted different steps of the angiogenic pathway. Table 1 Selected VEGF-targeted anti-angiogenics and their therapeutic indications Full size table. Clinical approach to cardiovascular toxicity of antiangiogenic therapy.

Full size image. Table 2 Different delivery methods for nanoparticles Full size table. Conclusion Anti-angiogenic therapy in cancers has enormous potentials using VEGF signaling pathways.

Availability of data and materials Not applicable. References GBD Disease and Injury Incidence and Prevalence Collaborators. Google Scholar Gupta K, Zhang J. Article CAS PubMed PubMed Central Google Scholar Kim KJ, Li B, Winer B, Armanini M, Gillett N, Philips HS, et al.

CAS Google Scholar Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Article CAS PubMed Google Scholar Planchard D, Planchard D. Article CAS PubMed Google Scholar Shih T, Lindley C.

Article CAS PubMed Google Scholar Wilhelm SM, Carter C, Tang L, Wilkie D, Mcnabola A, Rong H, et al. Article CAS PubMed Google Scholar Chase DM, Chaplin DJ, Monk BJ.

Article CAS PubMed Google Scholar Kazazi-Hyseni F, Beijnen JH, Schellens JH. Article CAS PubMed PubMed Central Google Scholar Ferrara N, Kerbel RS. Article CAS PubMed Google Scholar Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al.

Article CAS PubMed Google Scholar Miles DW, Chan A, Dirix LY, Corte J. Article CAS PubMed Google Scholar Robert NJ, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, et al.

Article CAS PubMed Google Scholar Tabernero J, Van Cutsem E, Lakomy R, Prausova J, Ruff P, Prausova J, et al. Article CAS PubMed Google Scholar Ramlau R, Gorbunova V, Ciuleanu TE, Novello S, Ozguroglu M, Goksel T, et al.

Article CAS PubMed Google Scholar Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-carbonero R, et al. Article CAS PubMed Google Scholar Maj E, Papiernik D, Wietrzyk J.

Article CAS PubMed PubMed Central Google Scholar Li J-L, Sainson RCA, Oon CE, Turley H, Leek R, Sheldon H, et al. Article CAS PubMed Google Scholar Clarke JM, Hurwitz HI.

Article CAS PubMed PubMed Central Google Scholar Balamurugan K. Article CAS PubMed Google Scholar Jeong W, Rapisarda A, Ryun S, Robert P, Chen A, Melillo G, et al. Article CAS PubMed Google Scholar Eatock MM, Tebbutt NC, Bampton CL, Strickland AH, Van Cutsem E, Nanayakkara N, et al. Article CAS PubMed Google Scholar Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, et al.

Article CAS PubMed PubMed Central Google Scholar Loges S, Schmidt T, Carmeliet P. Article CAS PubMed PubMed Central Google Scholar Viallard C, Larrivee B. Article CAS PubMed Google Scholar Shojaei F, Ferrara N. Article CAS PubMed Google Scholar Orimo A, Gupta PB, Sgroi DC, Arenzana-seisdedos F, Delaunay T, Naeem R, et al.

Article CAS PubMed Google Scholar Guo W, Giancotti FG. Article CAS PubMed Google Scholar Yu JL, Rak JW, Coomber BL, Hicklin DJ, Kerbel RS. Article CAS Google Scholar Zarrin B, Zarifi F, Vaseghi G, Javanmard SH.

Article CAS Google Scholar Goel S, Wong AH, Jain RK. Article Google Scholar Ramjiawan RR, Griffioen AW, Duda DG.

Article PubMed PubMed Central Google Scholar Yasuda S, Sho M, Yamato I, Yoshiji H, Wakatsuki K, Nishiwada S, et al.

Angiogenesis is the Anti-angiogenesis in regenerative medicine of new Lycopene and heart health vessels. This process involves the migration, regeneratife, and medocine of endothelial cellsmedicije line Meeicine inside wall of blood vessels. The process of angiogenesis is controlled by chemical signals in the Hydration supplements for youth. Some of these signals, such as vascular endothelial growth factor VEGFbind to receptors on the surface of normal endothelial cells. When VEGF and other endothelial growth factors bind to their receptors on endothelial cells, signals within these cells are initiated that promote the growth and survival of new blood vessels. Other chemical signals, called angiogenesis inhibitorsinterfere with blood vessel formation. Normally, the angiogenesis stimulating and inhibiting effects of these chemical signals are balanced so that blood vessels form only when and where they are needed, such as during growth and healing.

Anti-angiogenesis in regenerative medicine -

Masaki I Angiogenic gene therapy for experimental critical limb ischemia: acceleration of limb loss by overexpression of vascular endothelial growth factor but not of fibroblast growth factor Mintzer MA, Simanek EE Nonviral vectors for gene delivery.

Misteli H, Wolff T, Füglistaler P, Gianni-Barrera R, Gürke L, Heberer M, Banfi A High-throughput flow cytometry purification of transduced progenitors expressing defined levels of vascular endothelial growth factor induces controlled angiogenesis in vivo.

Stem Cells — Mittermayr R, Morton T, Hofmann M, Helgerson S, Van Griensven M, Redl H Sustained rh VEGF release from a sprayed fibrin biomatrix induces angiogenesis, up-regulation of endogenous VEGF-R2, and reduces ischemic flap necrosis.

Wound Repair Regen — Mujagic E, Gianni-Barrera R, Trani M, Patel A, Gürke L, Heberer M, Wolff T, Banfi A Induction of aberrant vascular growth, but not of Normal angiogenesis, by cell-based expression of different doses of human and mouse VEGF is species-dependent.

Hum Gene Ther Methods — Norgren L, Hiatt WR, Dormandy JA et al Inter-society consensus for the management of peripheral arterial disease TASC II. J Vasc Surg S5—S Ostman A, Andersson M, Betsholtz C, Westermark B, Heldin CH Identification of a cell retention signal in the B-chain of platelet-derived growth factor and in the long splice version of the A-chain.

Cell Regul — Ozawa CR, Banfi A, Glazer NL, Thurston G, Springer ML, Kraft PE, McDonald DM, Blau HM Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis.

J Clin Invest — Park JE, Keller GA, Ferrara N The vascular endothelial growth factor VEGF isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF.

Mol Biol Cell — Lab Investig — Phelps EA, Headen DM, Taylor WR, Thulé PM, García AJ Vasculogenic bio-synthetic hydrogel for enhancement of pancreatic islet engraftment and function in type 1 diabetes.

Potente M, Gerhardt H, Carmeliet P Basic and therapeutic aspects of angiogenesis. Cell — Reginato S, Gianni-Barrera R, Banfi A Taming of the wild vessel: promoting vessel stabilization for safe therapeutic angiogenesis: figure 1.

Ribatti D, Vacca A, Nico B, Roncali L, Dammacco F Postnatal vasculogenesis. Mech Dev — Ribatti D, Nico B, Crivellato E Morphological and molecular aspects of physiological vascular morphogenesis. Rissanen TT, Korpisalo P, Markkanen JE, Liimatainen T, Ordén MR, Kholová I, De Goede A, Heikura T, Gröhn OH, Ylä-Herttuala S Blood flow remodels growing vasculature during vascular endothelial growth factor gene therapy and determines between capillary arterialization and sprouting angiogenesis.

Robinson CJ, Stringer SE The splice variants of vascular endothelial growth factor VEGF and their receptors. J Cell Sci — Rouwkema J, Rivron NC, van Blitterswijk CA Vascularization in tissue engineering. Trends Biotechnol — Rufaihah AJ, Johari NA, Vaibavi SR, Plotkin M, Di Thien DT, Kofidis T, Seliktar D Dual delivery of VEGF and ANG-1 in ischemic hearts using an injectable hydrogel.

Acta Biomater — Ruhrberg C, Gerhardt H, Golding M, Watson R, Ioannidou S, Fujisawa H, Betsholtz C, Shima DT Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis.

Sacchi V, Mittermayr R, Hartinger J, Martino MM, Lorentz KM, Wolbank S, Hofmann A, Largo RA, Marschall JS, Groppa E, Gianni-Barrera R, Ehrbar M, Hubbell JA, Redl H, Banfi A Long-lasting fibrin matrices ensure stable and functional angiogenesis by highly tunable, sustained delivery of recombinant VEGF Sakiyama-Elbert SE, Hubbell JA Controlled release of nerve growth factor from a heparin-containing fibrin-based cell ingrowth matrix.

J Control Release — Sakiyama-Elbert SE, Panitch A, Hubbell JA Development of growth factor fusion proteins for cell-triggered drug delivery.

Schense JC, Hubbell JA Cross-linking exogenous bifunctional peptides into fibrin gels with factor XIIIa. Bioconjug Chem — Scherberich A, Müller AM, Schäfer DJ, Banfi A, Martin I Adipose tissue-derived progenitors for engineering osteogenic and vasculogenic grafts.

J Cell Physiol — Schönherr E, Hausser HJ Extracellular matrix and cytokines: a functional unit. Dev Immunol — Schultz GS, Wysocki A Interactions between extracellular matrix and growth factors in wound healing. Schwarz ER, Speakman MT, Patterson M, Hale SS, Isner JM, Kedes LH, Kloner RA Evaluation of the effects of intramyocardial injection of DNA expressing vascular endothelial growth factor VEGF in a myocardial infarction model in the rat-angiogenesis and angioma formation.

J Am Coll Cardiol — Sharmin F, McDermott C, Lieberman J, Sanjay A, Khan Y Dual growth factor delivery from biofunctionalized allografts: sequential VEGF and BMP-2 release to stimulate allograft remodeling. J Orthop Res — Silva AKA, Richard C, Bessodes M, Scherman D, Merten OW Growth factor delivery approaches in hydrogels.

Biomacromolecules — Sims DE The pericyte-a review. Tissue Cell — Springer ML, Chen AS, Kraft PE, Bednarski M, Blau HM VEGF gene delivery to muscle: potential role for vasculogenesis in adults.

Mol Cell — Stratman AN, Malotte KM, Mahan RD, Davis MJ, Davis GE Pericyte recruitment during vasculogenic tube assembly stimulates endothelial basement membrane matrix formation. Am J Pathol — Tafuro S, Ayuso E, Zacchigna S, Zentilin L, Moimas S, Dore F, Giacca M Inducible adeno-associated virus vectors promote functional angiogenesis in adult organisms via regulated vascular endothelial growth factor expression.

Tayalia P, Mooney DJ Controlled growth factor delivery for tissue engineering. Adv Mater — Traub S, Morgner J, Martino MM, Höning S, Swartz MA, Wickström SA, Hubbell JA, Eming SA The promotion of endothelial cell attachment and spreading using FNIII10 fused to VEGF-A Upton Z, Cuttle L, Noble A, Kempf M, Topping G, Malda J, Xie Y, Mill J, Harkin DG, Kravchuk O, Leavesley DI, Kimble RM Vitronectin: growth factor complexes hold potential as a wound therapy approach.

J Invest Dermatol — Vajanto I, Rissanen TT, Rutanen J, Hiltunen MO, Tuomisto TT, Arve K, Närvänen O, Manninen H, Räsänen H, Hippeläinen M, Alhava E, Ylä-Herttuala S Evaluation of angiogenesis and side effects in ischemic rabbit hindlimbs after intramuscular injection of adenoviral vectors encoding VEGF and LacZ.

Villemejane J, Mir LM Physical methods of nucleic acid transfer: general concepts and applications. Br J Pharmacol — von Degenfeld G, Banfi A, Springer ML, Wagner RA, Jacobi J, Ozawa CR, Merchant MJ, Cooke JP, Blau HM Microenvironmental VEGF distribution is critical for stable and functional vessel growth in ischemia.

Ylä-Herttuala S, Markkanen JE, Rissanen TT Gene therapy for ischemic cardiovascular diseases: some lessons learned from the first clinical trials. Trends Cardiovasc Med — Zisch AH Cell-demanded release of VEGF from synthetic, biointeractive cell-ingrowth matrices for vascularized tissue growth.

Zisch AH, Lutolf MP, Hubbell JA Biopolymeric delivery matrices for angiogenic growth factors. Cardiovasc Pathol — Download references.

Lily Xiang Laboratory, Genomic Institute of Novartis Research Foundation, San Diego, CA, USA. Ludwig Boltzmann Institute for Experimental and Clinical Traumatology, AUVA Research Center, Vienna, Austria.

Laboratory for Cell and Tissue Engineering, Department of Obstetrics, University Hospital Zurich, Zurich, Switzerland. You can also search for this author in PubMed Google Scholar. Correspondence to Rainer Mittermayr. AUVA Research Center, Ludwig Boltzmann Inst.

Clinical AUVA Research Center, Wien, Vatican City State. Department of Biomedicine, University Hospital Basel Department of Biomedicine, Basel, Switzerland. Institute for Pathology, Johannes Gutenberg University Institute for Pathology, Mainz, Germany.

Reprints and permissions. Sacchi, V. Therapeutic Angiogenesis in Regenerative Medicine. In: Holnthoner, W. eds Vascularization for Tissue Engineering and Regenerative Medicine. Reference Series in Biomedical Engineering. Springer, Cham. Received : 27 January Accepted : 03 October Published : 12 December Publisher Name : Springer, Cham.

Print ISBN : Online ISBN : eBook Packages : Springer Reference Engineering Reference Module Computer Science and Engineering. Policies and ethics. Skip to main content.

Abstract A vascular network along with a sufficient blood supply is not only essential for physiological maintenance of tissue viability but is also a prerequisite for any approaches in regenerative medicine.

References Al-Dosari MS, Gao X Nonviral gene delivery: principle, limitations, and recent progress. AAPS J — CrossRef Google Scholar Anderson EM, Silva EA, Hao Y, Martinick KD, Vermillion SA, Stafford AG, Doherty EG, Wang L, Doherty EJ, Grossman PM, Mooney DJ VEGF and IGF delivered from alginate hydrogels promote stable perfusion recovery in ischemic hind limbs of aged mice and young rabbits.

J Vasc Res — CrossRef Google Scholar Annex BH Therapeutic angiogenesis for critical limb ischaemia. Nat Rev Cardiol — CrossRef Google Scholar Asahara T, Murohara T, Sullivan A, Silver M, Van Der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM Isolation of putative progenitor endothelial cells for angiogenesis.

Science 80 — CrossRef Google Scholar Bae H, Puranik AS, Gauvin R, Edalat F, Carrillo-Conde B, Peppas NA, Khademhosseini A Building vascular networks. Sci Transl Med ps23—ps23 CrossRef Google Scholar Banfi A, von Degenfeld G, Blau HM Critical role of microenvironmental factors in angiogenesis.

Curr Atheroscler Rep — CrossRef Google Scholar Banfi A, von Degenfeld G, Gianni-Barrera R, Reginato S, Merchant MJ, McDonald DM, Blau HM Therapeutic angiogenesis due to balanced single-vector delivery of VEGF and PDGF-BB.

FASEB J — CrossRef Google Scholar Benjamin EJ, Blaha MJ, Chiuve SE et al Heart disease and stroke statistics update: a report from the American Heart Association. Circulation e CrossRef Google Scholar Benjamin EJ et al Heart disease and stroke statistics update: a report from the American Heart Association.

PMID: Berlin DH, Platz A, Berlin D-, Höpfner M, Noble F, Medizin MM, Secomb TW. Mol Asp Med S1—S27 CrossRef Google Scholar Capila I, Linhardt RJ Heparin-protein interactions.

Angew Chem Int Ed Engl — CrossRef Google Scholar Carmeliet P, Jain RK Molecular mechanisms and clinical applications of angiogenesis. Nature — CrossRef Google Scholar Carmeliet P, De Smet F, Loges S, Mazzone M Branching morphogenesis and antiangiogenesis candidates: tip cells lead the way.

Nat Rev Clin Oncol — CrossRef Google Scholar Chen RR, Mooney DJ Polymeric growth factor delivery strategies for tissue engineering. Pharm Res — CrossRef Google Scholar De Laporte L, Rice JJ, Tortelli F, Hubbell JA, Tenascin C Promiscuously binds growth factors via its fifth fibronectin type III-like domain.

PLoS One 8:e CrossRef Google Scholar De Spiegelaere W, Casteleyn C, Van Den Broeck W, Plendl J, Bahramsoltani M, Simoens P, Djonov V, Cornillie P Intussusceptive angiogenesis: a biologically relevant form of angiogenesis.

J Vasc Res — CrossRef Google Scholar Dor Y, Djonov V, Abramovitch R, Itin A, Fishman GI, Carmeliet P, Goelman G, Keshets E Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy.

EMBO J — CrossRef Google Scholar Dragneva G, Korpisalo P, Yla-Herttuala S Promoting blood vessel growth in ischemic diseases: challenges in translating preclinical potential into clinical success. Dis Model Mech — CrossRef Google Scholar Drury JL, Mooney DJ Hydrogels for tissue engineering: scaffold design variables and applications.

Biomaterials — CrossRef Google Scholar Edelstein ML, Abedi MR, Wixon J Gene therapy clinical trials worldwide to —an update.

J Gene Med — CrossRef Google Scholar Egginton S, Zhou AL, Brown MD, Hudlická O Unorthodox angiogenesis in skeletal muscle. Cardiovasc Res — CrossRef Google Scholar Ehrbar M, Djonov VG, Schnell C, Tschanz SA, Martiny-Baron G, Schenk U, Wood J, Burri PH, Hubbell JA, Zisch AH Cell-demanded liberation of VEGF from fibrin implants induces local and controlled blood vessel growth.

Circ Res — CrossRef Google Scholar Ehrbar M, Rizzi SC, Hlushchuk R, Djonov V, Zisch AH, Hubbell JA, Weber FE, Lutolf MP Enzymatic formation of modular cell-instructive fibrin analogs for tissue engineering.

Biomaterials — CrossRef Google Scholar Ehrbar M, Zeisberger SM, Raeber GP, Hubbell JA, Schnell C, Zisch AH The role of actively released fibrin-conjugated VEGF for VEGF receptor 2 gene activation and the enhancement of angiogenesis.

Biomaterials — CrossRef Google Scholar Ellertsdóttir E, Lenard A, Blum Y, Krudewig A, Herwig L, Affolter M, Belting HG Vascular morphogenesis in the zebrafish embryo. Dev Biol —65 CrossRef Google Scholar Fantin A, Vieira JM, Gestri G, Denti L, Schwarz Q, Prykhozhij S, Peri F, Wilson SW, Ruhrberg C Tissue macrophages act as cellular chaperones for vascular anastomosis downstream of VEGF-mediated endothelial tip cell induction.

Blood — CrossRef Google Scholar Gaengel K, Genové G, Armulik A, Betsholtz C Endothelial-mural cell signaling in vascular development and angiogenesis. Arterioscler Thromb Vasc Biol — CrossRef Google Scholar Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A, Abramsson A, Jeltsch M, Mitchell C, Alitalo K, Shima D, Betsholtz C VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia.

J Cell Biol — CrossRef Google Scholar Giacca M, Zacchigna S VEGF gene therapy: therapeutic angiogenesis in the clinic and beyond.

Gene Ther — CrossRef Google Scholar Gianni-Barrera R, Trani M, Reginato S, Banfi A To sprout or to split? Biochem Soc Trans — CrossRef Google Scholar Gianni-Barrera R, Trani M, Fontanellaz C, Heberer M, Djonov V, Hlushchuk R, Banfi A VEGF over-expression in skeletal muscle induces angiogenesis by intussusception rather than sprouting.

Angiogenesis — CrossRef Google Scholar Hanahan D Signaling vascular morphogenesis and maintenance. Science —50 CrossRef Google Scholar Heil M, Schaper W Cellular mechanisms of arteriogenesis. EXS — Google Scholar Heil M, Eitenmüller I, Schmitz-Rixen T, Schaper W Arteriogenesis versus angiogenesis: similarities and differences.

J Cell Mol Med —55 CrossRef Google Scholar Hellström M, Kalén M, Lindahl P, Abramsson A, Betsholtz C Role of PDGF-B and PDGFR-β in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse.

Development — Google Scholar Hellström M, Phng L-K, Hofmann JJ, Wallgard E, Coultas L, Lindblom P, Alva J, Nilsson A-K, Karlsson L, Gaiano N, Yoon K, Rossant J, Iruela-Arispe ML, Kalén M, Gerhardt H, Betsholtz C Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis.

Nature — CrossRef Google Scholar Herwig L, Blum Y, Krudewig A, Ellertsdottir E, Lenard A, Belting HG, Affolter M Distinct cellular mechanisms of blood vessel fusion in the zebrafish embryo. Curr Biol — CrossRef Google Scholar Hynes RO The extracellular matrix: not just pretty fibrils.

Science — CrossRef Google Scholar Iruela-Arispe ML, Davis GE Cellular and molecular mechanisms of vascular lumen formation. Dev Cell — CrossRef Google Scholar Jain RK Molecular regulation of vessel maturation.

Nat Med — CrossRef Google Scholar Johnson PC, Mikos AG, Fisher JP, Jansen JA Strategic directions in tissue engineering. Tissue Eng — CrossRef Google Scholar Jones N, Iljin K, Dumont DJ, Alitalo K Tie receptors: new modulators of angiogenic and lymphangiogenic responses.

Nat Rev Mol Cell Biol — CrossRef Google Scholar Karvinen H, Ylä-Herttuala S New aspects in vascular gene therapy.

Curr Opin Pharmacol — CrossRef Google Scholar Kässmeyer S, Plendl J, Custodis P, Bahramsoltani M New insights in vascular development: vasculogenesis and endothelial progenitor cells.

Anat Histol Embryol —11 CrossRef Google Scholar Lee KY, Mooney DJ Hydrogels for tissue engineering. Chem Rev — CrossRef Google Scholar Lee RJ, Springer ML, Blanco-Bose WE, Shaw R, Ursell PC, Blau HM VEGF Gene delivery to myocardium deleterious effects of unregulated expression.

Circulation — CrossRef Google Scholar Lindblom P, Gerhardt H, Liebner S, Abramsson A, Enge M, Hellström M, Bäckström G, Fredriksson S, Landegren U, Nyström HC, Bergström G, Dejana E, Östman A, Lindahl P, Betsholtz C Endothelial PDGF-B retention is required for proper investment of pericytes in the microvessel wall.

Genes Dev — CrossRef Google Scholar Lorentz KM, Kontos S, Frey P, Hubbell JA Engineered aprotinin for improved stability of fibrin biomaterials. Biomaterials — CrossRef Google Scholar Macri L, Silverstein D, Clark RAF Growth factor binding to the pericellular matrix and its importance in tissue engineering.

Adv Drug Deliv Rev — CrossRef Google Scholar Makanya AN, Hlushchuk R, Djonov VG Intussusceptive angiogenesis and its role in vascular morphogenesis, patterning, and remodeling. Angiogenesis — CrossRef Google Scholar Martino MM, Hubbell JA The 12thth type III repeats of fibronectin function as a highly promiscuous growth factor-binding domain.

FASEB J — CrossRef Google Scholar Martino MM, Tortelli F, Mochizuki M, Traub S, Ben-David D, Kuhn GA, Muller R, Livne E, Eming SA, Hubbell JA Engineering the growth factor microenvironment with fibronectin domains to promote wound and bone tissue healing.

Sci Transl Med ra89—ra89 CrossRef Google Scholar Martino MM, Briquez PS, Ranga A, Lutolf MP, Hubbell JA Heparin-binding domain of fibrin ogen binds growth factors and promotes tissue repair when incorporated within a synthetic matrix. Proc Natl Acad Sci — CrossRef Google Scholar Martino MM, Briquez PS, Guc E, Tortelli F, Kilarski WW, Metzger S, Rice JJ, Kuhn GA, Muller R, Swartz MA, Hubbell JA Growth factors engineered for super-affinity to the extracellular matrix enhance tissue healing.

Science — CrossRef Google Scholar Martino MM, Brkic S, Bovo E, Burger M, Schaefer DJ, Wolff T, Gürke L, Briquez PS, Larsson HM, Gianni-Barrera R, Hubbell JA, Banfi A Extracellular matrix and growth factor engineering for controlled angiogenesis in regenerative medicine.

Front Bioeng Biotechnol CrossRef Google Scholar Masaki I Angiogenic gene therapy for experimental critical limb ischemia: acceleration of limb loss by overexpression of vascular endothelial growth factor but not of fibroblast growth factor Circ Res — CrossRef Google Scholar Mintzer MA, Simanek EE Nonviral vectors for gene delivery.

Chem Rev — CrossRef Google Scholar Misteli H, Wolff T, Füglistaler P, Gianni-Barrera R, Gürke L, Heberer M, Banfi A High-throughput flow cytometry purification of transduced progenitors expressing defined levels of vascular endothelial growth factor induces controlled angiogenesis in vivo.

Stem Cells — CrossRef Google Scholar Mittermayr R, Morton T, Hofmann M, Helgerson S, Van Griensven M, Redl H Sustained rh VEGF release from a sprayed fibrin biomatrix induces angiogenesis, up-regulation of endogenous VEGF-R2, and reduces ischemic flap necrosis.

Wound Repair Regen — CrossRef Google Scholar Mujagic E, Gianni-Barrera R, Trani M, Patel A, Gürke L, Heberer M, Wolff T, Banfi A Induction of aberrant vascular growth, but not of Normal angiogenesis, by cell-based expression of different doses of human and mouse VEGF is species-dependent.

Hum Gene Ther Methods —37 CrossRef Google Scholar Norgren L, Hiatt WR, Dormandy JA et al Inter-society consensus for the management of peripheral arterial disease TASC II.

J Vasc Surg S5—S67 CrossRef Google Scholar Ostman A, Andersson M, Betsholtz C, Westermark B, Heldin CH Identification of a cell retention signal in the B-chain of platelet-derived growth factor and in the long splice version of the A-chain.

On the other hand, ischemic tissues are already vascularized and proangiogenic therapy aims at expanding the microvascular networks to promote collateral artery remodeling and restore physiological blood flow.

For example, adenoviral vectors combine two clinically desirable features, namely robustness of expression and transient duration, limited by the immune response.

However, these same features compromise safety by uncontrolled distribution of high levels and efficacy by regression of unstable vessels. Based on recent advances in elucidating the molecular regulation of the switch between normal and aberrant angiogenesis and of vascular stabilization, as described above, it can be envisioned that local delivery of VEGF-expressing adenoviral vectors might be complemented by systemic treatment with drugs targeting ancillary pathways eg, EphB4 or Sema3A signaling , to ensure a safe and effective outcome while exploiting the clinically attractive features of VEGF gene therapy.

is supported by the Swiss National Science Foundation , the European Union H Program and , the Swiss Nanoscience Institute KOKORO , and intramural grants from the Department of Surgery of Basel University Hospital.

Data sharing is not applicable to this article as no new data were created or analyzed in this study. Marsano A , Medeiros da Cunha CM , Ghanaati S , et al.

Spontaneous in vivo Chondrogenesis of bone marrow-derived mesenchymal progenitor cells by blocking vascular endothelial growth factor signaling. Stem Cells Translational Medicine. Google Scholar. Benjamin EJ , Muntner P , Alonso A , et al.

Heart disease and stroke statistics update: a report from the American Heart Association. Everett E , Mathioudakis N. Update on management of diabetic foot ulcers. Ann N Y Acad Sci. Rouwkema J , Rivron NC , van Blitterswijk CA. Vascularization in tissue engineering.

Trends Biotechnol. Garcia JR , Garcia AJ. Biomaterial-mediated strategies targeting vascularization for bone repair. Drug Deliv Transl Res. Lopes D , Martins-Cruz C , Oliveira MB , Mano JF. Bone physiology as inspiration for tissue regenerative therapies. Scheufler O , Schaefer DJ , Jaquiery C , et al.

Spatial and temporal patterns of bone formation in ectopically pre-fabricated, autologous cell-based engineered bone flaps in rabbits. J Cell Mol Med. Senger DR , Galli SJ , Dvorak AM , Perruzzi C , Harvey V , Dvorak H.

Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Keck PJ , Hauser SD , Krivi G , et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF.

Leung DW , Cachianes G , Kuang WJ , Goeddel D , Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Gupta R , Tongers J , Losordo DW.

Human studies of angiogenic gene therapy. Circ Res. Carmeliet P , Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Annex BH. Therapeutic angiogenesis for critical limb ischaemia. Nat Rev Cardiol.

Korpisalo P , Yla-Herttuala S. Stimulation of functional vessel growth by gene therapy. Integr Biol. Tischer E , Mitchell R , Hartman T , et al. The human gene for vascular endothelial growth factor.

Multiple protein forms are encoded through alternative exon splicing. J Biol Chem. Ferrara N. Binding to the extracellular matrix and proteolytic processing: two key mechanisms regulating vascular endothelial growth factor action. Mol Biol Cell. Lampropoulou A , Ruhrberg C.

Neuropilin regulation of angiogenesis. Biochem Soc Trans. Harper SJ , Bates DO. VEGF-A splicing: the key to anti-angiogenic therapeutics?

Nat Rev Cancer. Ruhrberg C , Gerhardt H , Golding M , et al. Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis.

Genes Dev. Gerhardt H , Golding M , Fruttiger M , et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol. Betz C , Lenard A , Belting HG , Affolter M.

Cell behaviors and dynamics during angiogenesis. Fantin A , Vieira JM , Gestri G , et al. Tissue macrophages act as cellular chaperones for vascular anastomosis downstream of VEGF-mediated endothelial tip cell induction.

Hellstrom M , Phng LK , Hofmann JJ , et al. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Gianni-Barrera R , Bartolomeo M , Vollmar B , Djonov V , Banfi A. Split for the cure: VEGF, PDGF-BB and intussusception in therapeutic angiogenesis.

Egginton S , Zhou AL , Brown MD , Hudlická O. Unorthodox angiogenesis in skeletal muscle. Cardiovasc Res. Gianni-Barrera R , Trani M , Fontanellaz C , et al. VEGF over-expression in skeletal muscle induces angiogenesis by intussusception rather than sprouting. Al Haj Zen A , Oikawa A , Bazan-Peregrino M , et al.

Inhibition of delta-likemediated signaling impairs reparative angiogenesis after ischemia. Makanya AN , Hlushchuk R , Djonov VG.

Intussusceptive angiogenesis and its role in vascular morphogenesis, patterning, and remodeling. Egginton S.

Invited review: activity-induced angiogenesis. Pflugers Arch. De Spiegelaere W , Casteleyn C , Van den Broeck W , et al. Intussusceptive angiogenesis: a biologically relevant form of angiogenesis.

J Vasc Res. Dimova I , Hlushchuk R , Makanya A , et al. Inhibition of notch signaling induces extensive intussusceptive neo-angiogenesis by recruitment of mononuclear cells.

Dill MT , Rothweiler S , Djonov V , et al. Disruption of Notch1 induces vascular remodeling, intussusceptive angiogenesis, and angiosarcomas in livers of mice. e - Gianni-Barrera R , Butschkau A , Uccelli A , et al. PDGF-BB regulates splitting angiogenesis in skeletal muscle by limiting VEGF-induced endothelial proliferation.

Groppa E , Brkic S , Uccelli A , et al. EMBO Rep. Bjarnegard M , Enge M , Norlin J , et al. Endothelium-specific ablation of PDGFB leads to pericyte loss and glomerular, cardiac and placental abnormalities.

Lindahl P , Johansson BR , Leveen P , et al. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Lindblom P , Gerhardt H , Liebner S , et al.

Endothelial PDGF-B retention is required for proper investment of pericytes in the microvessel wall. Armulik A , Genove G , Betsholtz C.

Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev Cell. Sato Y , Rifkin DB. Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-beta 1-like molecule by plasmin during co-culture.

Goumans MJ , Valdimarsdottir G , Itoh S , Rosendahl A , Sideras P , ten Dijke P. Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J. van Meeteren LA , ten Dijke P. Regulation of endothelial cell plasticity by TGF-beta.

Cell Tissue Res. Fagiani E , Christofori G. Angiopoietins in angiogenesis. Cancer Lett. Pasquale EB. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Erber R , Eichelsbacher U , Powajbo V , et al. EphB4 controls blood vascular morphogenesis during postnatal angiogenesis.

Foo SS , Turner CJ , Adams S , et al. Ephrin-B2 controls cell motility and adhesion during blood-vessel-wall assembly. Sawamiphak S , Seidel S , Essmann CL , et al.

Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. Wang Y , Nakayama M , Pitulescu ME , et al. Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. Murdoch C , Muthana M , Coffelt SB , Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis.

Grunewald M , Avraham I , Dor Y , et al. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Dimova I , Karthik S , Makanya A , et al. De Palma M , Naldini L. Tie2-expressing monocytes TEMs : novel targets and vehicles of anticancer therapy?

Biochim Biophys Acta. Zacchigna S , Pattarini L , Zentilin L , et al. Bone marrow cells recruited through the neuropilin-1 receptor promote arterial formation at the sites of adult neoangiogenesis in mice.

J Clin Invest. Groppa E , Brkic S , Bovo E , et al. EMBO Mol Med. Lee RJ , Springer ML , Blanco-Bose WE , Shaw R , Ursell PC , Blau HM. VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Schwarz ER , Speakman MT , Patterson M , et al. Evaluation of the effects of intramyocardial injection of DNA expressing vascular endothelial growth factor VEGF in a myocardial infarction model in the rat—angiogenesis and angioma formation.

J Am Coll Cardiol. Springer ML , Chen AS , Kraft PE , et al. VEGF gene delivery to muscle: potential role for vasculogenesis in adults. Mol Cell. Sundberg C , Nagy JA , Brown LF , et al. Am J Pathol. Ozawa CR , Banfi A , Glazer NL , et al. Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis.

von Degenfeld G , Banfi A , Springer ML , et al. Microenvironmental VEGF distribution is critical for stable and functional vessel growth in ischemia.

FASEB J. Boden J , Lassance-Soares RM , Wang H , et al. Vascular regeneration in ischemic Hindlimb by adeno-associated virus expressing conditionally silenced vascular endothelial growth factor.

J Am Heart Assoc. Ylä-Herttuala S , Baker AH. Cardiovascular gene therapy: past, present, and future. Mol Ther. Misteli H , Wolff T , Fuglistaler P , et al. High-throughput flow cytometry purification of transduced progenitors expressing defined levels of vascular endothelial growth factor induces controlled angiogenesis in vivo.

Stem Cells. Helmrich U , Marsano A , Melly L , et al. Tissue Eng Part C Methods. Wolff T , Mujagic E , Gianni-Barrera R , et al. FACS-purified myoblasts producing controlled VEGF levels induce safe and stable angiogenesis in chronic hind limb ischemia.

Melly LF , Marsano A , Frobert A , et al. Controlled angiogenesis in the heart by cell-based expression of specific vascular endothelial growth factor levels.

Hum Gene Ther Methods. Melly L , Cerino G , Frobert A , et al. Myocardial infarction stabilization by cell-based expression of controlled vascular endothelial growth factor levels. Marsano A , Maidhof R , Luo J , et al. The effect of controlled expression of VEGF by transduced myoblasts in a cardiac patch on vascularization in a mouse model of myocardial infarction.

Boccardo S , Gaudiello E , Melly L , et al. Engineered mesenchymal cell-based patches as controlled VEGF delivery systems to induce extrinsic angiogenesis.

Acta Biomater. Helmrich U , Di Maggio N , Guven S , et al. Osteogenic graft vascularization and bone resorption by VEGF-expressing human mesenchymal progenitors. Browne S , Pandit A. Engineered systems for therapeutic angiogenesis.

Curr Opin Pharmacol. Martino MM , Brkic S , Bovo E , et al. Extracellular matrix and growth factor engineering for controlled angiogenesis in regenerative medicine.

Front Bioeng Biotechnol. Addi C , Murschel F , De Crescenzo G. Design and use of chimeric proteins containing a collagen-binding domain for wound healing and bone regeneration. Tissue Eng Part B Rev. Bao P , Kodra A , Tomic-Canic M , Golinko MS , Ehrlich HP , Brem H. The role of vascular endothelial growth factor in wound healing.

J Surg Res. Zisch AH , Schenk U , Schense JC , Sakiyama-Elbert SE , Hubbell JA. Covalently conjugated VEGF—fibrin matrices for endothelialization.

J Control Release. Sacchi V , Mittermayr R , Hartinger J , et al. Long-lasting fibrin matrices ensure stable and functional angiogenesis by highly tunable, sustained delivery of recombinant VEGF Proc Natl Acad Sci USA.

Martino MM , Tortelli F , Mochizuki M , et al. Engineering the growth factor microenvironment with fibronectin domains to promote wound and bone tissue healing. Sci Transl Med. Martino MM , Briquez PS , Guc E , et al. Growth factors engineered for super-affinity to the extracellular matrix enhance tissue healing.

Reevaluation of the role of VEGF-B suggests a restricted role in the revascularization of the ischemic myocardium. Arterioscler Thromb Vasc Biol. Kivela R , Bry M , Robciuc MR , et al. VEGF-B-induced vascular growth leads to metabolic reprogramming and ischemia resistance in the heart.

Lahteenvuo JE , Lahteenvuo MT , Kivela A , et al. Vascular endothelial growth factor-B induces myocardium-specific angiogenesis and arteriogenesis via vascular endothelial growth factor receptor and neuropilin receptordependent mechanisms.

Rissanen TT , Markkanen JE , Gruchala M , et al. VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. Health USNIo. Adenovirus Vascular Endothelial Growth Factor D AdvVEGF-D Therapy for Treatment of Refractory Angina Pectoris ReGenHeart.

Accessed September 24, Hartikainen J , Hassinen I , Hedman A , et al. Eur Heart J. Banfi A , von Degenfeld G , Gianni-Barrera R , et al. Therapeutic angiogenesis due to balanced single-vector delivery of VEGF and PDGF-BB.

Gianni-Barrera R , Burger M , Wolff T , et al. Long-term safety and stability of angiogenesis induced by balanced single-vector co-expression of PDGF-BB and VEGF in skeletal muscle. Sci Rep.

Korpisalo P , Karvinen H , Rissanen TT , et al. Vascular endothelial growth factor-a and platelet-derived growth factor-B combination gene therapy prolongs angiogenic effects via recruitment of interstitial mononuclear cells and paracrine effects rather than improved pericyte coverage of angiogenic vessels.

Kupatt C , Hinkel R , Pfosser A , et al. Cotransfection of vascular endothelial growth factor-a and platelet-derived growth factor-B via recombinant adeno-associated virus resolves chronic ischemic malperfusion. Role of vessel maturation. Richardson TP , Peters MC , Ennett AB , Mooney DJ.

Polymeric system for dual growth factor delivery. Nat Biotechnol. Thurston G , Suri C , Smith K , et al. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin Amelioration of sepsis by TIE2 activation-induced vascular protection.

Dor Y , Djonov V , Abramovitch R , et al. Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. Tafuro S , Ayuso E , Zacchigna S , et al. Inducible adeno-associated virus vectors promote functional angiogenesis in adult organisms via regulated vascular endothelial growth factor expression.

Dai Y , Schwarz EM , Gu D , Zhang WW , Sarvetnick N , Verma IM.

Hydration supplements for youth of Anri-angiogenesis Engineering volume 12 reegnerative, Article Anti-angiogenesis in regenerative medicine 36 Cite this article. Metrics regenegative. Angiogenesis Nutritional support for digestion touted as a fundamental procedure in the regeneration and restoration of different tissues. The induction of de novo blood vessels seems to be vital to yield a successful cell transplantation rate loaded on various scaffolds. Scaffolds are natural or artificial substances that are considered as one of the means for delivering, aligning, maintaining cell connection in a favor of angiogenesis. Journal of the Egyptian Mddicine Cancer Institute Anti-angiogenesis in regenerative medicine 33Article Anti-angiofenesis 15 Cite this article. Metrics details. Anti-angiogensis is regenerativr formation of new Millet grain benefits networks from preexisting ones through regennerative migration and proliferation of differentiated endothelial cells. Available evidence suggests that while antiangiogenic therapy could inhibit tumour growth, the response to these agents is not sustained. The aim of this paper was to review the evidence for anti-angiogenic therapy in cancer therapeutics and the mechanisms and management of tumour resistance to antiangiogenic agents. We also explored the latest advances and challenges in this field.